Clozapine
- Generic Name
- Clozapine
- Brand Names
- Clozaril, Fazaclo, Versacloz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19ClN4
- CAS Number
- 5786-21-0
- Unique Ingredient Identifier
- J60AR2IKIC
- Background
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramida...
- Indication
Clozapine is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine should be used only in patients who have failed to respond adequately to standard antipsychotic treatment.
...
- Associated Conditions
- Suicidal Behaviour, Treatment Resistant Schizophrenia, Advanced dopaminomimetic psychosis
- Associated Therapies
- -
Characterizing Response to Antipsychotics in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- The Royal Ottawa Mental Health Centre
- Target Recruit Count
- 40
- Registration Number
- NCT06159322
- Locations
- 🇨🇦
The Royal's Institute of Mental Health Research, Ottawa, Ontario, Canada
Observation of Clozapine Treatment Safety in Bipolar Disorder.
- Conditions
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Medical University of Gdansk
- Target Recruit Count
- 30
- Registration Number
- NCT06011460
- Locations
- 🇵🇱
Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Pomorskie, Poland
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
- Conditions
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Dr. Inge Winter
- Target Recruit Count
- 418
- Registration Number
- NCT05958875
- Locations
- 🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇮🇹Università degli studi della Campania Luigi Vanvitelli, Naples, Italy
🇮🇹Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino", Turin, Italy
An Exploratory Analysis of Immune and Inflammatory Response Associated with Clozapine
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 60
- Registration Number
- NCT05741502
- Locations
- 🇺🇸
Ohio State University Harding Hospital, Columbus, Ohio, United States
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Dr. Inge Winter
- Target Recruit Count
- 1254
- Registration Number
- NCT05603104
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Biomarkers in Clozapine-responding Schizophrenia
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2022-04-07
- Target Recruit Count
- 200
- Registration Number
- NCT05316883
- Locations
- 🇩🇰
Mental Health Services Glostrup, Unit for Complicated Schizophrenia, Glostrup, Denmark
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 280
- Registration Number
- NCT05208190
- Locations
- 🇺🇸
Augusta University Research Institute, Inc., Augusta, Georgia, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of Maryland School of Medicine, Baltimore, Maryland, United States
CLOZAPINE Response in Biotype-1
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 524
- Registration Number
- NCT04580134
- Locations
- 🇺🇸
Hartford Healthcare, Hartford, Connecticut, United States
🇺🇸University of Georgia, Athens, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 162
- Registration Number
- NCT04528095
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
- Conditions
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-03-20
- Target Recruit Count
- 75
- Registration Number
- NCT04529226
- Locations
- 🇪🇸
Unidad de Salud Mental Comunitaria Andújar, Andújar, Spain
🇪🇸Hospital Universitario Reina Sofía, Córdoba, Spain
🇪🇸Hospital Universitario de Jerez, Jerez De La Frontera, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.